Figure S5. Tumor weight and flow cytometry analysis of tumor infiltrating leukocytes in EMT6-HER2 tumor model. (A) Tumor weight of Fig. 5A. (B-D) Gating strategy for flow cytometry analysis of immune subset in tumor samples. (E-H) EMT6-HER2 tumor were treated with control (0.9%NaCl), trastuzumab (1 mg/kg), Tras-DXd (1 mg/kg), or Tras-DXd-MTL1 (1 mg/kg) for 2 days (n=5), and immune subsets in tumor tissue were analyzed by flow cytometry, and the proportion macrophages (E), CD86+ macrophages (F), CD206+ macrophages (G), and CD3+T cells (H) were shown. The data were shown as mean ± SEM, One-way ANOVA (A, E-G) with Tukey’s correction were used for multiple comparisons. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.